Introducing EMD-RX9!

EMD-RX9 is a high-potency, highly bioavailable capsule aimed at becoming a prescription medication due to its capacity of more than 150mg of CBD.

“The higher dose strength and potency of EMD-RX9 will support Emyria’s US-focused registration programs by helping address the needs of patients requiring high CBD doses,” said Emyria (ASX:EMD) CEO Dr Michael Winlo.

EMD-RX9 will aim to enter Phase 1 clinical trials in the second half of 2023.

Read more: https://investorhub.emyria.com/4350140